Evaluating the Scientific Evidence
for Potential Reduced-Risk Tobacco Products
Biological Effects
Assessment (BEA) Committee
Meeting #2: September 27-28, 2005
Day One: September 27 (8 a.m. - 6 p.m.)
  Executive Session (8 a.m. - 6 p.m.)
  I.  Opening Remarks and Review of Agenda
  II.  Overview of Chronic Obstructive Pulmonary Disease (COPD) Biomarkers
  III.  Overview of Cardiovascular Disease (CVD) Biomarkers
  IV.  Overview of Lung Cancer Biomarkers
  V.  Wrap-up of COPD, CVD, and Lung Cancer Biomarkers

Close (6 p.m.)
Day Two: September 28 (8 a.m. - 3 p.m.)
  Executive Session (8 a.m. - 3 p.m.)
  I.  Discussion of a Potential Biomarker Strategy for Testing Reduced Risk Products
  II.  Discussion of the Limits of Potential Biomarkers and Critical Aspects of Future Biomarker Development
  III.  Discussion of Biomarker Definitions
  IV.  Discussion of Committee needs for literature, presentations, etc.
Discussion of BEA meeting schedule

Adjourn (3 p.m.)